Literature DB >> 11252410

Release of mast cell tryptase from human colorectal mucosa in inflammatory bowel disease.

M Raithel1, S Winterkamp, A Pacurar, P Ulrich, J Hochberger, E G Hahn.   

Abstract

BACKGROUND: Histologic detection of mast cells cannot adequately reflect their function and state of activation, since degranulated mast cells may escape from histologic assessment. To better define the role of mast cells in inflammatory bowel disease, the spontaneous secretion of mast cell tryptase, a highly mast cell specific protease, was measured from colorectal samples.
METHODS: After detection of the initial basal tryptase release, gut mucosal samples were incubated in a modified Hanks/RPM1 medium using a mucosa oxygenation system. Spontaneous tryptase secretion from 153 viable samples of 22 controls, 30 patients with Crohn disease (CD) and 19 with ulcerative colitis (UC) was followed over 4 h. Tryptase was measured by radioimmunoassay.
RESULTS: The rates of the initial basal tryptase release revealed that mast cell activation occurs during active inflammation in CD and UC. While the time course of tryptase release was similar in all three groups, spontaneous tryptase secretion (over 4 h) was found to be significantly enhanced and prolonged only in UC (P < 0.01 compared to controls), but not in CD.
CONCLUSIONS: This study provides clear evidence from viable endoscopic colorectal samples that mast cell mediators were secreted during active inflammation in CD and UC. However, the extent of mast cell involvement and activation differs considerably between CD and UC. Significantly increased rates of tryptase secretion were found both in non-inflamed and inflamed tissue of UC, indicating that mast cell involvement is a typical feature of UC.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11252410     DOI: 10.1080/003655201750065933

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  46 in total

Review 1.  Biopsy interpretation of colonic biopsies when inflammatory bowel disease is excluded.

Authors:  Tze S Khor; Hiroshi Fujita; Koji Nagata; Michio Shimizu; Gregory Y Lauwers
Journal:  J Gastroenterol       Date:  2012-02-10       Impact factor: 7.527

Review 2.  Protease-activated receptors: regulation of neuronal function.

Authors:  Toshiyuki Saito; Nigel W Bunnett
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

3.  Protease-activated receptors as therapeutic targets in visceral pain.

Authors:  Nicolas Cenac
Journal:  Curr Neuropharmacol       Date:  2013-12       Impact factor: 7.363

4.  Protective effect of proteinase-activated receptor 2 activation on motility impairment and tissue damage induced by intestinal ischemia/reperfusion in rodents.

Authors:  Fiore Cattaruzza; Nicolas Cenac; Elisabetta Barocelli; Mariannina Impicciatore; Eric Hyun; Nathalie Vergnolle; Catia Sternini
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

5.  Protease-activated receptor 2, dipeptidyl peptidase I, and proteases mediate Clostridium difficile toxin A enteritis.

Authors:  Graeme S Cottrell; Silvia Amadesi; Stella Pikios; Eric Camerer; J Adam Willardsen; Brett R Murphy; George H Caughey; Paul J Wolters; Shaun R Coughlin; Anders Peterson; Wolfgang Knecht; Charalabos Pothoulakis; Nigel W Bunnett; Eileen F Grady
Journal:  Gastroenterology       Date:  2007-04-13       Impact factor: 22.682

Review 6.  Enteric bacterial proteases in inflammatory bowel disease- pathophysiology and clinical implications.

Authors:  Ian M Carroll; Nitsan Maharshak
Journal:  World J Gastroenterol       Date:  2013       Impact factor: 5.742

7.  Promoter methylation of protease-activated receptor (PAR2) is associated with severe clinical phenotypes of ulcerative colitis (UC).

Authors:  Tomomitsu Tahara; Tomoyuki Shibata; Masakatsu Nakamura; Hiromi Yamashita; Daisuke Yoshioka; Masaaki Okubo; Naoko Maruyama; Toshiaki Kamano; Yoshio Kamiya; Hiroshi Fujita; Yoshihito Nakagawa; Mitsuo Nagasaka; Masami Iwata; Kazuya Takahama; Makoto Watanabe; Hiroshi Nakano; Ichiro Hirata; Tomiyasu Arisawa
Journal:  Clin Exp Med       Date:  2009-01-30       Impact factor: 3.984

Review 8.  Proteinases, proteinase-activated receptors (PARs) and the pathophysiology of cancer and diseases of the cardiovascular, musculoskeletal, nervous and gastrointestinal systems.

Authors:  Kristina K Hansen; Katerina Oikonomopoulou; Yang Li; Morley D Hollenberg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-10-19       Impact factor: 3.000

9.  Contribution of bone marrow-derived cells to the pro-inflammatory effects of protease-activated receptor-2 in colitis.

Authors:  Eric Hyun; Patricia Andrade-Gordon; Martin Steinhoff; Paul L Beck; Nathalie Vergnolle
Journal:  Inflamm Res       Date:  2010-03-26       Impact factor: 4.575

10.  Relationship between mast cells and the colitis with relapse induced by trinitrobenzesulphonic acid in Wistar rats.

Authors:  Ana Carolina Luchini; Déborah Mara Costa de Oliveira; Cláudia Helena Pellizzon; Luiz Claudio Di Stasi; José Carlos Gomes
Journal:  Mediators Inflamm       Date:  2009-05-11       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.